Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-11

AUTHORS

R. P. Castleberry, A. H. Ragab, C. P. Steuber, B. Kamen, S. Toledano, K. Starling, D. Norris, P. Burger, J. P. Krischer

ABSTRACT

To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses. More... »

PAGES

401-406

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00198601

DOI

http://dx.doi.org/10.1007/bf00198601

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017171155

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2084075


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aziridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoquinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drugs, Investigational", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Alabama at Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "The Departments of Pediatrics of the University of Alabama at Birmingham, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castleberry", 
        "givenName": "R. P.", 
        "id": "sg:person.0626116531.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626116531.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Emory University", 
          "id": "https://www.grid.ac/institutes/grid.189967.8", 
          "name": [
            "Emory University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ragab", 
        "givenName": "A. H.", 
        "id": "sg:person.010643352004.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010643352004.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor University", 
          "id": "https://www.grid.ac/institutes/grid.252890.4", 
          "name": [
            "Baylor University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steuber", 
        "givenName": "C. P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "University of Texas Southwestern Medical School, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kamen", 
        "givenName": "B.", 
        "id": "sg:person.0616713135.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616713135.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Miami", 
          "id": "https://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "University of Miami, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toledano", 
        "givenName": "S.", 
        "id": "sg:person.01242012473.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242012473.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "West Virginia University", 
          "id": "https://www.grid.ac/institutes/grid.268154.c", 
          "name": [
            "West Virginia University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "K.", 
        "id": "sg:person.065570553.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "The Cleveland Clinics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Norris", 
        "givenName": "D.", 
        "id": "sg:person.01141744115.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141744115.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burger", 
        "givenName": "P.", 
        "id": "sg:person.0653131115.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653131115.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Florida", 
          "id": "https://www.grid.ac/institutes/grid.15276.37", 
          "name": [
            "The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krischer", 
        "givenName": "J. P.", 
        "id": "sg:person.015434510637.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015434510637.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00165153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002279955", 
          "https://doi.org/10.1007/bf00165153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00165185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002576749", 
          "https://doi.org/10.1007/bf00165185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00180194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009528930", 
          "https://doi.org/10.1007/bf00180194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(84)90193-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012921883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031779669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00148387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041519111", 
          "https://doi.org/10.1007/bf00148387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00148387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041519111", 
          "https://doi.org/10.1007/bf00148387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00153636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045673869", 
          "https://doi.org/10.1007/bf00153636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00153636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045673869", 
          "https://doi.org/10.1007/bf00153636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.3.464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079514700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079995803", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080114927", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081779436", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081874945", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081908006", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082281986", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1990-11", 
    "datePublishedReg": "1990-11-01", 
    "description": "To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00198601", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693162", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693295", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693270", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors", 
    "pagination": "401-406", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "51cf607a92c430b57f26f5fc6a457aaa25027bd012fb2000825f0f7c54c6a306"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2084075"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00198601"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017171155"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00198601", 
      "https://app.dimensions.ai/details/publication/pub.1017171155"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130794_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00198601"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      57 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00198601 schema:about N34998394644841ddbd5b8d7bd290d899
2 N3dd76ea3fe3e4f689477eae1d4571989
3 N4fd1d97ace764f0f818788bd8f7d0492
4 N51a1eee500f84d599218d6be2f2c3458
5 N58b471488ab344c88be0e179aa5f3785
6 N75038a36b8ea450fa6959b2859ab25db
7 Naa594f3974054d4fb3305bb9f27042ba
8 Nc2c5c4c8592449859651ce75b93c0bb4
9 Nc896d2740d9c4436b85208fd1512c205
10 Nd4705b68072747f7bc52be7cdcfe108f
11 Nd8d8f8d405474d5995a811e5e1c05eb3
12 Ne1b1d13552514e38b13d188a31ba135e
13 Nea82c21f4eb54e628f119530eb4d024e
14 Nf3fdbf32937e43c29042d91f2f6473a2
15 anzsrc-for:11
16 anzsrc-for:1109
17 schema:author Nf42dc43d8d944eddbb7fd75bd67a569f
18 schema:citation sg:pub.10.1007/bf00148387
19 sg:pub.10.1007/bf00153636
20 sg:pub.10.1007/bf00165153
21 sg:pub.10.1007/bf00165185
22 sg:pub.10.1007/bf00180194
23 https://app.dimensions.ai/details/publication/pub.1079995803
24 https://app.dimensions.ai/details/publication/pub.1080114927
25 https://app.dimensions.ai/details/publication/pub.1081779436
26 https://app.dimensions.ai/details/publication/pub.1081874945
27 https://app.dimensions.ai/details/publication/pub.1081908006
28 https://app.dimensions.ai/details/publication/pub.1082281986
29 https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v
30 https://doi.org/10.1016/0277-5379(84)90193-7
31 https://doi.org/10.1200/jco.1987.5.3.464
32 schema:datePublished 1990-11
33 schema:datePublishedReg 1990-11-01
34 schema:description To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N48ad6354b2ce4f518c337e9b96af3ce1
39 Nabc3329f75e44221a3a222d684979e6c
40 sg:journal.1094201
41 schema:name Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors
42 schema:pagination 401-406
43 schema:productId N3d0d12ee7b9b437c80357547198c1159
44 N5c02565455394141814a720a208e72ed
45 N5c229ec1751a4a53862ea950530f3fa2
46 N73840308a44345faacabc1d61da430d3
47 Ncb5ada9248ac48508b266e8f9fb41210
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017171155
49 https://doi.org/10.1007/bf00198601
50 schema:sdDatePublished 2019-04-11T13:49
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N7a46b9f74c0d433184a36ad79688a24f
53 schema:url http://link.springer.com/10.1007/BF00198601
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N28aec19844014371be575f313c65345a rdf:first sg:person.0616713135.35
58 rdf:rest N4dacc87ebf9641e1a32a23c01e52f2c6
59 N34998394644841ddbd5b8d7bd290d899 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Adolescent
61 rdf:type schema:DefinedTerm
62 N359d4d2b24534d1ba5683354e1e2a0ee rdf:first sg:person.01141744115.25
63 rdf:rest N4baad94f4d0747f78c4df4e30d14b348
64 N3d0d12ee7b9b437c80357547198c1159 schema:name nlm_unique_id
65 schema:value 8309330
66 rdf:type schema:PropertyValue
67 N3dd76ea3fe3e4f689477eae1d4571989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Drug Evaluation
69 rdf:type schema:DefinedTerm
70 N48ad6354b2ce4f518c337e9b96af3ce1 schema:issueNumber 4
71 rdf:type schema:PublicationIssue
72 N4baad94f4d0747f78c4df4e30d14b348 rdf:first sg:person.0653131115.45
73 rdf:rest Nb5a40b8f66814c809b4a5a69f01a87b9
74 N4dacc87ebf9641e1a32a23c01e52f2c6 rdf:first sg:person.01242012473.51
75 rdf:rest N67d76ba80b9949828d15f4b46375f4bb
76 N4fd1d97ace764f0f818788bd8f7d0492 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Drugs, Investigational
78 rdf:type schema:DefinedTerm
79 N51a1eee500f84d599218d6be2f2c3458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Antineoplastic Agents
81 rdf:type schema:DefinedTerm
82 N58b471488ab344c88be0e179aa5f3785 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Child
84 rdf:type schema:DefinedTerm
85 N5c02565455394141814a720a208e72ed schema:name pubmed_id
86 schema:value 2084075
87 rdf:type schema:PropertyValue
88 N5c229ec1751a4a53862ea950530f3fa2 schema:name doi
89 schema:value 10.1007/bf00198601
90 rdf:type schema:PropertyValue
91 N67d76ba80b9949828d15f4b46375f4bb rdf:first sg:person.065570553.31
92 rdf:rest N359d4d2b24534d1ba5683354e1e2a0ee
93 N73840308a44345faacabc1d61da430d3 schema:name dimensions_id
94 schema:value pub.1017171155
95 rdf:type schema:PropertyValue
96 N75038a36b8ea450fa6959b2859ab25db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Benzoquinones
98 rdf:type schema:DefinedTerm
99 N7a46b9f74c0d433184a36ad79688a24f schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 N97ebabb9f01f49f7b695207feb68f685 schema:name The Cleveland Clinics, USA
102 rdf:type schema:Organization
103 Na17b22cd27f44eb6805d1bb3a6e5138f schema:affiliation https://www.grid.ac/institutes/grid.252890.4
104 schema:familyName Steuber
105 schema:givenName C. P.
106 rdf:type schema:Person
107 Naa594f3974054d4fb3305bb9f27042ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Neoplasm Recurrence, Local
109 rdf:type schema:DefinedTerm
110 Nabc3329f75e44221a3a222d684979e6c schema:volumeNumber 8
111 rdf:type schema:PublicationVolume
112 Nb5a40b8f66814c809b4a5a69f01a87b9 rdf:first sg:person.015434510637.88
113 rdf:rest rdf:nil
114 Nc2c5c4c8592449859651ce75b93c0bb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Neoplasms
116 rdf:type schema:DefinedTerm
117 Nc30550849a4243dba6ee3229eaddce06 rdf:first sg:person.010643352004.84
118 rdf:rest Nd502f466f567491dbdc7e294c8f58346
119 Nc896d2740d9c4436b85208fd1512c205 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Adult
121 rdf:type schema:DefinedTerm
122 Ncb5ada9248ac48508b266e8f9fb41210 schema:name readcube_id
123 schema:value 51cf607a92c430b57f26f5fc6a457aaa25027bd012fb2000825f0f7c54c6a306
124 rdf:type schema:PropertyValue
125 Nd4705b68072747f7bc52be7cdcfe108f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aziridines
127 rdf:type schema:DefinedTerm
128 Nd502f466f567491dbdc7e294c8f58346 rdf:first Na17b22cd27f44eb6805d1bb3a6e5138f
129 rdf:rest N28aec19844014371be575f313c65345a
130 Nd8d8f8d405474d5995a811e5e1c05eb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Child, Preschool
132 rdf:type schema:DefinedTerm
133 Ne1b1d13552514e38b13d188a31ba135e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Drug Administration Schedule
135 rdf:type schema:DefinedTerm
136 Nea82c21f4eb54e628f119530eb4d024e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Brain Neoplasms
138 rdf:type schema:DefinedTerm
139 Nf3fdbf32937e43c29042d91f2f6473a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 Nf42dc43d8d944eddbb7fd75bd67a569f rdf:first sg:person.0626116531.27
143 rdf:rest Nc30550849a4243dba6ee3229eaddce06
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
148 schema:name Neurosciences
149 rdf:type schema:DefinedTerm
150 sg:grant.2693162 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
151 rdf:type schema:MonetaryGrant
152 sg:grant.2693270 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
153 rdf:type schema:MonetaryGrant
154 sg:grant.2693295 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
155 rdf:type schema:MonetaryGrant
156 sg:journal.1094201 schema:issn 0167-6997
157 1573-0646
158 schema:name Investigational New Drugs
159 rdf:type schema:Periodical
160 sg:person.010643352004.84 schema:affiliation https://www.grid.ac/institutes/grid.189967.8
161 schema:familyName Ragab
162 schema:givenName A. H.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010643352004.84
164 rdf:type schema:Person
165 sg:person.01141744115.25 schema:affiliation N97ebabb9f01f49f7b695207feb68f685
166 schema:familyName Norris
167 schema:givenName D.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141744115.25
169 rdf:type schema:Person
170 sg:person.01242012473.51 schema:affiliation https://www.grid.ac/institutes/grid.26790.3a
171 schema:familyName Toledano
172 schema:givenName S.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242012473.51
174 rdf:type schema:Person
175 sg:person.015434510637.88 schema:affiliation https://www.grid.ac/institutes/grid.15276.37
176 schema:familyName Krischer
177 schema:givenName J. P.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015434510637.88
179 rdf:type schema:Person
180 sg:person.0616713135.35 schema:affiliation https://www.grid.ac/institutes/grid.267313.2
181 schema:familyName Kamen
182 schema:givenName B.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616713135.35
184 rdf:type schema:Person
185 sg:person.0626116531.27 schema:affiliation https://www.grid.ac/institutes/grid.265892.2
186 schema:familyName Castleberry
187 schema:givenName R. P.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626116531.27
189 rdf:type schema:Person
190 sg:person.0653131115.45 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
191 schema:familyName Burger
192 schema:givenName P.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653131115.45
194 rdf:type schema:Person
195 sg:person.065570553.31 schema:affiliation https://www.grid.ac/institutes/grid.268154.c
196 schema:familyName Starling
197 schema:givenName K.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31
199 rdf:type schema:Person
200 sg:pub.10.1007/bf00148387 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041519111
201 https://doi.org/10.1007/bf00148387
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/bf00153636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045673869
204 https://doi.org/10.1007/bf00153636
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/bf00165153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002279955
207 https://doi.org/10.1007/bf00165153
208 rdf:type schema:CreativeWork
209 sg:pub.10.1007/bf00165185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002576749
210 https://doi.org/10.1007/bf00165185
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/bf00180194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009528930
213 https://doi.org/10.1007/bf00180194
214 rdf:type schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1079995803 schema:CreativeWork
216 https://app.dimensions.ai/details/publication/pub.1080114927 schema:CreativeWork
217 https://app.dimensions.ai/details/publication/pub.1081779436 schema:CreativeWork
218 https://app.dimensions.ai/details/publication/pub.1081874945 schema:CreativeWork
219 https://app.dimensions.ai/details/publication/pub.1081908006 schema:CreativeWork
220 https://app.dimensions.ai/details/publication/pub.1082281986 schema:CreativeWork
221 https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1031779669
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/0277-5379(84)90193-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012921883
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1987.5.3.464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079514700
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.15276.37 schema:alternateName University of Florida
228 schema:name The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
231 schema:name Duke University Medical Center, USA
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.189967.8 schema:alternateName Emory University
234 schema:name Emory University, USA
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.252890.4 schema:alternateName Baylor University
237 schema:name Baylor University, USA
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.265892.2 schema:alternateName University of Alabama at Birmingham
240 schema:name The Departments of Pediatrics of the University of Alabama at Birmingham, USA
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.267313.2 schema:alternateName The University of Texas Southwestern Medical Center
243 schema:name University of Texas Southwestern Medical School, USA
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.26790.3a schema:alternateName University of Miami
246 schema:name University of Miami, USA
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.268154.c schema:alternateName West Virginia University
249 schema:name West Virginia University, USA
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...